These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 27422147

  • 1. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
    Teusink-Cross A, Davies SM, Danziger-Isakov L, El-Bietar J, Grimley MS.
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
    [Abstract] [Full Text] [Related]

  • 2. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
    Zembles TN, Gaertner KM, Gutzeit MF, Willoughby RE.
    Am J Health Syst Pharm; 2016 Mar 15; 73(6):405-8. PubMed ID: 26953285
    [Abstract] [Full Text] [Related]

  • 3. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R, Wolfler A, Picone S, Rossi GA, Gualberti G, Merolla R, Del Vecchio A, Villani A, Midulla F, Dotta A.
    Ital J Pediatr; 2019 Nov 09; 45(1):139. PubMed ID: 31706338
    [Abstract] [Full Text] [Related]

  • 4. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.
    J Manag Care Pharm; 2010 Nov 09; 16(1):15-22. PubMed ID: 20044843
    [Abstract] [Full Text] [Related]

  • 5. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.
    Belleudi V, Trotta F, Pinnarelli L, Davoli M, Addis A.
    Arch Dis Child; 2018 Dec 09; 103(12):1163-1167. PubMed ID: 30217858
    [Abstract] [Full Text] [Related]

  • 6. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee.
    Pediatrics; 2014 Aug 09; 134(2):e620-38. PubMed ID: 25070304
    [Abstract] [Full Text] [Related]

  • 7. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb 09; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 8. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.
    Health Technol Assess; 2008 Dec 09; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus.
    Blake SM, Tanaka D, Bendz LM, Staebler S, Brandon D.
    Adv Neonatal Care; 2017 Aug 09; 17(4):292-298. PubMed ID: 27926583
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.
    Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.
    J Virol; 2017 Aug 01; 91(15):. PubMed ID: 28539438
    [Abstract] [Full Text] [Related]

  • 13. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA.
    Sci Transl Med; 2017 May 03; 9(388):. PubMed ID: 28469033
    [Abstract] [Full Text] [Related]

  • 14. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
    Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L.
    J Infect Dis; 2001 Aug 01; 184(3):350-4. PubMed ID: 11443562
    [Abstract] [Full Text] [Related]

  • 15. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP, Lee SWH.
    Pharmacotherapy; 2017 Jun 01; 37(6):755-769. PubMed ID: 28423192
    [Abstract] [Full Text] [Related]

  • 16. A multicenter investigation of respiratory syncytial viral infection in children with hematopoietic cell transplantation.
    Rowan CM, Gertz SJ, Zinter MS, Moffet J, Bajwa RPS, Barnum JL, Kong M, Hematopoietic Cell Transplant group of the Pediatric Acute Lung Injury and Sepsis Investigator (PALISI) network.
    Transpl Infect Dis; 2018 Jun 01; 20(3):e12882. PubMed ID: 29573141
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravenous palivizumab in respiratory syncytial virus infection after hematopoietic stem cell transplant in children.
    Torres JP, Tapia LI, Catalán P, De la Maza V, Mejías A.
    Pediatr Blood Cancer; 2017 Dec 01; 64(12):. PubMed ID: 28598593
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.